BioSpectrum the business of Bio & Health Sciences ASIA EDITION

BMS gets FDA approval for metastatic melanoma drug

23 December 2014 | News | By BioSpectrum Bureau

BMS gets FDA approval for metastatic melanoma drug



Singapore: Bristol-Myers Squibb has recieved US Food and Drug Administration (FDA) approval for Opdivo (nivolumab) injection, for intravenous use.

Opdivo is a human programmed death receptor-1 (PD-1) blocking antibody indicated for the treatment of patients with unresectable or metastatic melanoma.

Metastatic melanoma is the deadliest form of skin cancer, and despite recent advances, there are limited treatment options available for patients who have been previously treated with approved agents.

"Bristol-Myers Squibb is pleased to be able to offer an important new option for patients who have progressed following treatment for unresectable or metastatic melanoma, which is one of the most aggressive forms of cancer," said Mr Lamberto Andreotti, chief executive officer, Bristol-Myers Squibb.